​This project aims to identify metabolic profiles and surrogate patterns for drug therapeutics using a metabolomics approach, in collaboration with King Faisal Specialist Hospital & Research Centre (KFSHRC) and The Jordan Center for Pharmaceutical Research. By leveraging advanced mass spectrometry-based metabolomics, we will analyze metabolic alterations associated with drug response and resistance. This study seeks to uncover key biomarkers that can serve as indicators for therapeutic efficacy and toxicity, ultimately guiding precision medicine strategies. The collaboration will integrate expertise in clinical metabolomics and pharmaceutical research to enhance drug development and personalized treatment approaches.

The Project is Funded by KFSHRC​

​​